Mostrar el registro sencillo del ítem

dc.contributor.advisorSossa Melo, Claudia Lucía
dc.contributor.advisorOchoa Vera, Miguel Enrique
dc.contributor.authorOrtiz Tarazona, Selena María Fernanda
dc.coverage.spatialColombiaspa
dc.date.accessioned2021-11-24T20:58:53Z
dc.date.available2021-11-24T20:58:53Z
dc.date.issued2021
dc.identifier.urihttp://hdl.handle.net/20.500.12749/15040
dc.description.abstractIntroducción: La leucemia mieloide aguda (LMA) es la leucemia aguda más común en adultos, con una sobrevida global a 5 años de 27.7%, sin embargo comparado con periodos anteriores esta ha mejorado gracias a una mejor comprensión de los distintos factores pronósticos que incluyen los relacionados al paciente y a la enfermedad, pero suimpacto sobre los resultados clínicos de los pacientes con LMA de la clínica FOSCAL no se conocen. Objetivo: Identificar factores de asociación pronósticos respecto a la supervivencia global y supervivencia libre de eventos, en la cohorte de pacientes con leucemia mieloide aguda de la clínica FOSCAL, en el periodo comprendido entre el 01 de enero de 2009 al 30 de junio de 2021. Materiales y métodos: se registró retrospectivamente información sociodemográfica y de características clínicas de los pacientes con LMA atendidos en la FOSCAL. Se describen las características de los pacientes al diagnóstico; Análisis Kaplan Meier fue usado para evaluar la sobrevida global y sobrevida libre de eventos. Tambien se realizo calculo de hazzard ratio e intervalos de confianza del 95% crudos y ajustados por covariables.spa
dc.description.tableofcontentsPlanteamiento Del Problema Y Justificación ......................................................................................... 8 Marco Teórico Y Estado Del Arte ......................................................................................................... 12 Leucemia Mieloide Aguda ........................................................................................................................... 12 Diagnóstico Y Clasificación .......................................................................................................................... 15 Morfológico ......................................................................................................................... 15 Inmunofenotipo .................................................................................................................. 16 Citogenética ........................................................................................................................ 16 Biología Molecular .............................................................................................................. 16 Clasificación ......................................................................................................................... 17 Estratificación Y Factores Pronósticos ..................................................................................................... 19 Factores Pronósticos Pretratemiento ................................................................................. 20 Factores Post-Tratamiento .................................................................................................. 22 Tratamiento ..................................................................................................................................................... 23 Tratamiento De Inducción .................................................................................................. 23 Tratamiento Post Remisión ................................................................................................. 24 Pregunta De Investigación ................................................................................................................... 25 Hipótesis ........................................................................................................................................................... 25 Objetivos .............................................................................................................................................. 26 Objetivo General ............................................................................................................................................ 26 Objetivos Específicos ..................................................................................................................................... 26 Metodología ........................................................................................................................................ 27 Tipo De Estudio ............................................................................................................................................... 27 Población .......................................................................................................................................................... 27 Criterios De Inclusión Y Exclusión .............................................................................................................. 27 Cálculo De Tamaño Muestral ..................................................................................................................... 27 Recolección De Información ....................................................................................................................... 28 Variables ........................................................................................................................................................... 28 Plan De Procesamiento Y Análisis De Datos ........................................................................................... 28 Consideraciones Éticas ................................................................................................................................. 29 Discusión .............................................................................................................................................. 54 Conclusiones ........................................................................................................................................ 63 Referencias Bibliográficas .................................................................................................................... 65 Anexos .........................................................................................spa
dc.format.mimetypeapplication/pdfspa
dc.language.isospaspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/*
dc.titleFactores pronósticos y su impacto en los resultados clínicos en pacientes con leucemia mieloide agudaspa
dc.title.translatedPrognostic factors and their impact on clinical outcomes in patients with acute myeloid leukemiaspa
dc.degree.nameEspecialista en Medicina Internaspa
dc.publisher.grantorUniversidad Autónoma de Bucaramanga UNABspa
dc.rights.localAbierto (Texto Completo)spa
dc.publisher.facultyFacultad Ciencias de la Saludspa
dc.publisher.programEspecialización en Medicina Internaspa
dc.description.degreelevelEspecializaciónspa
dc.type.driverinfo:eu-repo/semantics/masterThesis
dc.type.localTesisspa
dc.type.coarhttp://purl.org/coar/resource_type/c_bdcc
dc.subject.keywordsInternal medicinespa
dc.subject.keywordsMedicinespa
dc.subject.keywordsMedical sciencesspa
dc.subject.keywordsHealth sciencesspa
dc.subject.keywordsLeukemiasspa
dc.subject.keywordsNeoplasiaspa
dc.subject.keywordsPrecancerous conditionsspa
dc.subject.keywordsMeasurable residual diseasespa
dc.subject.keywordsAMLspa
dc.subject.keywordsGenetic abnormalitiesspa
dc.identifier.instnameinstname:Universidad Autónoma de Bucaramanga - UNABspa
dc.identifier.reponamereponame:Repositorio Institucional UNABspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersion
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.relation.references1. The Global Cancer Observatory - All Rights Reserved - May, 2019.spa
dc.relation.references2. Kolitz, JE. (2017) Overview of acute myeloid leukemia in adults. En Larson, RA (Ed), uptodate, 2020.spa
dc.relation.references3. Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Rev. 2019;36:70-87. Doi:10.1016/j.blre.2019.04.005spa
dc.relation.references4. Siegel, Rebeca et al, cancer statistics 2020, CA CANCER J CLIN 2020;70:7–3, .doi: 10.3322/caac.21590. Available online at cacancerjournal.comspa
dc.relation.references5. Situación de cáncer en la población adulta atendida en el SGSSS de Colombia 2019, Cuenta de Alto Costo. Fondo Colombia de Enfermedades de alto costo (2019)spa
dc.relation.references6. Short, NJ, Rytting, ME y Cortes, JE (2018). Leucemia mieloide aguda. The Lancet, 392 (10147), 593–606. Doi: 10.1016 / s0140-6736 (18) 31041-9spa
dc.relation.references7. Schuurhuis, G. J., Heuser, M, Freeman, S., Béné, M.-C, et al (2018). Minimal/measurable residual disease in AML: a consensus document from the European leukemianet MRD Working Party. Blood, 131(12), 1275–1291. Doi:10.1182/blood-2017-09-801498spa
dc.relation.references8. Consenso basado en la evidencia: Indicadores de gestión del riesgo en adultos con leucemia linfoide aguda y leucemia mieloide aguda en Colombia, Fondo Colombiano de Enfermedades de Alto Costo, marzo de 2018spa
dc.relation.references9. OECD Reviews of Health Systems: Colombia 2016 [En línea]. OECD Publishing; 2015 [cited 2017 Jul 13]. (OECD Reviews of Health Systems). Disponible en: http:// www.oecd ilibrary.org/social-issues-migration-health/oecd-reviews-of-health- systems-colombia 2015_9789264248908-enspa
dc.relation.references10. Valencia O, Lopes G, Sánchez P, Acuña L, Uribe D, González J. Incidence and Prevalence of Cancer in Colombia: The Methodology Used Matters. J Glob On- col [En línea]. 2017 Jul 6 [cited 2017 Jul 10];JGO.17.00008. Disponible en: http:// ascopubs.org/doi/10.1200/JGO.17.00008 
spa
dc.relation.references11. Ministerio de Salud y Protección Social - Instituto Nacional de Cancerología E. Plan Decenal para el control del cáncer Colombia, 2012-2021 [En línea]. Bogotá D.C.: Ministerio de Salud y Protección Social. MSPS; 2012 [cited 2016 Aug 23]. 124 p. Disponible en: http://www.iccp-portal.org/sites/default/ les/plans/Plan- Decenal_controlcancer_2012 2021.pdfspa
dc.relation.references12. CONTROL DEL CÁNCER, ACCESO Y DESIGUALDAD EN AMÉRICA LATINA Una historia de luces y sombras. [cited 2017 Jul 13]; Disponible en: https://www. Eiuperspectives.economist.com/sites/default/ les/images/Cancer_control_ac- cess_and_inequality_in_Latin_America_SPANISH.pdf 
spa
dc.relation.references13. Rubnitz Jeffrey et al, acute myeloid leukemia, Hematology/Oncology Clinics of North America, 2010-02-01, Volumen 24, Número 1, Páginas 35-63spa
dc.relation.references14. Howladern,nooneam,krapchom,millerd,bresta,yum,ruhlj,tatalovichz, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, editors. SEER Cancer sta- tistics review, 1975–2016. Bethesda, MD: National Cancer Institute; 2019https:// seer.cancer.gov/csr/1975_2016/ [based on November 2018 SEER data submission, posted to the SEER web site, April 2019. Accessed 4/18/2019].spa
dc.relation.references15. Gibson CJ, Steensma DP. Nuevas ideas de estudios de hematopoyesis clonal. Clin Cancer Res. 2018; 24 : 4633-4642spa
dc.relation.references16. Lacher MJ, Sussman LN. Leukemia and Hodgkin's disease. Ann Intern Med 1963;59:369– 78.spa
dc.relation.references17. Reimer RR, Hoover R, Fraumeni Jr. JF, Young RC. Acute leukemia after alkylating- agent therapy of ovarian cancer. N Engl J Med 1977;297:177–81spa
dc.relation.references18. Schonfeld SJ, Gilbert ES, Dores GM, Lynch CF, Hodgson DC, Hall P., et. Al .: Leucemia mieloide aguda después del linfoma de Hodgkin: un estudio poblacional de 35,511 pacientes. J Natl Cancer Inst 2006; 98: págs. 215-218spa
dc.relation.references19. Rosenstock AS, Niu J, Giordano SH, Zhao H, Wolff AC, Chavez-macgregor M. Acute myeloid leukemia and myelodysplastic syndrome after adjuvant che- motherapy: a population based study among older breast cancer patients. Cancer 2018;124:899–906.spa
dc.relation.references20. Zeidan AM, Long JB, Wang R, Hu X, Yu JB, Huntington SF, et al. Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: a population-based study. Plos One 2017;12:e0184747spa
dc.relation.references21. International Agency for Research on Cancer (IARC). Monographs on the eva- luation of the carcinogenic risk of chemicals to humans: Chemical agents and related occupations. Vol. 120. 2018.
spa
dc.relation.references22. Glass DC, Gray CN, Jolley DJ, Gibbons C, Sim MR. The health watch case-control study of leukemia and benzene: the story so far. Ann N Y Acad Sci 2006;1076:1080–9.
spa
dc.relation.references23. Estey EH. Acute myeloid leukemia: 2013 update on risk-stratification and management. Am J Hematol. 2013;88(4):318-327. Doi:10.1002/ajh.23404).spa
dc.relation.references24. Terry PD, Shore DL, Rauscher GH, Sandler DP. Occupation, hobbies, and acute leukemia in adults. Leuk Res 2005;29:1117–30spa
dc.relation.references25. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 2000;355:165–9.
)spa
dc.relation.references26. Li S, Chen L, Jin W, Ma X, Ma Y, Dong F, et al. Influence of body mass index on incidence and prognosis of acute myeloid leukemia and acute promyelocytic leukemia: a meta analysis. Sci Rep 2017;7:17998spa
dc.relation.references27. Reyner J, et al, Leucemias agudas, Farreras rozman, medicina interna,209. 1643-1659, mayo 2020.spa
dc.relation.references28. Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., Büchner, T. Bloomfield, C. D. (2017). Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood, 129(4), 424-447. Doi:10.1182/blood-2016-08 733196spa
dc.relation.references29. Arber DA. The 2016 WHO classification of acute myeloid leukemia: What the practicing clinician needs to know. Semin Hematol. 2019;56(2):90-95. Doi:10.1053/j.seminhematol.2018.08.002spa
dc.relation.references30. Delgadillo O, et al, Caracterización de los pacientes con Leucemia mieloide aguda FOSCAL, 2019.spa
dc.relation.references31. Sanz MA, Iacoboni G, Montesinos P, Venditti A. Emerging strategies for the treatment of older patients with acute myeloid leukemia. Ann Hematol. 2016;95(10):1583-1593. Doi:10.1007/s00277-016-2666spa
dc.relation.references30. Nagel G, Weber D, Fromm E, et al. Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population based registry study (AMLSG bio). Ann Hematol. 2017;96(12):1993-2003. Doi:10.1007/s00277-017-3150-3spa
dc.relation.references33. Brunner AM, Sadrzadeh H, Feng Y, et al. Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia. Am J Hematol. 2013;88(8):642-646. Doi:10.1002/ajh.23462spa
dc.relation.references34. Lancet, Terwijn M, van Putten WL, Kelder A, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol. 2013;31(31):3889-3897. Doi:10.1200/JCO.2012.45.9628spa
dc.relation.references35. Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 2017; 377: 454–64spa
dc.relation.references36. Tratamiento de la Leucemia Promielocítica Aguda de Nuevo Diagnóstico, protocolo PETHEMA LPA 2017spa
dc.relation.references37. Ardila M, et al, alteraciones metabólicas post-trasplante de progenitores hematopoyéticos en la foscal de 2009 al 2017. 2019spa
dc.relation.references38. Appelbaum FR. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia. Best Pract Res Clin Haematol. 2013;26(3):279-284. Doi:10.1016/j.beha.2013.10.008spa
dc.relation.references39 aribi K, Sobh M, Ghez D, Baugier de Materre A. Impact of age, functional status, and comorbidities on quality of life and outcomes in elderly patients with AML: review. Ann Hematol. 2021 Jun;100(6):1359-1376. doi: 10.1007/s00277-020-04375-x.spa
dc.relation.references40 Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, Anderson JE, Petersdorf SH. Age and acute myeloid leukemia. Blood. 2006 May 1;107(9):3481-5. doi: 10.1182/blood-2005-09-3724. Epub 2006spa
dc.relation.references41. Jung J, Cho B, Kim H, Han E, Jang W, Han K, Lee J, Chung N, Cho B, Kim M, Kim Y. Reclassification of Acute Myeloid Leukemia According to the 2016 WHO Classification. Ann Lab Med 2019;39:311-316 https://doi.org/10.3343/alm.2019.39.3.311spa
dc.relation.references42 Ana María Amor Vigil, La biología molecular en el diagnóstico de la leucemia mieloide aguda, Revista Cubana de Hematología, Inmunología y Hemoterapia. 2019; 35 (3): a_987, https://orcid.org/0000-0001-9182-2spa
dc.relation.references43 mith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J, Vardiman JW, Rowley JD, Larson RA. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003 Jul 1;102(1):43-52. doi: 10.1182/blood-2002-11-3343. Epub 2003 Mar 6. PMID: 12623843spa
dc.relation.references44 Hulegårdh E, Nilsson C, Lazarevic V, Garelius H, Antunovic P, Rangert Derolf Å, Möllgård L, Uggla B, Wennström L, Wahlin A, Höglund M, Juliusson G, Stockelberg D, Lehmann S. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. Am J Hematol. 2015 Mar;90(3):208-14. doi: 10.1002/ajh.23908. Epub 2015 Jan 16. PMID: 25421221.spa
dc.relation.references45 Granfeldt Østgård LS, Medeiros BC, Sengeløv H, Nørgaard M, Andersen MK, Dufva IH, Friis LS, Kjeldsen E, Marcher CW, Preiss B, Severinsen M, Nørgaard JM. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study. J Clin Oncol. 2015 Nov 1;33(31):3641-9. doi: 10.1200/JCO.2014.60.0890. Epub 2015 Aug 24. PMID: 26304885spa
dc.relation.references46 Finn L, Sproat L, Heckman MG, Jiang L, Diehl NN, Ketterling R, Tibes R, Valdez R, Foran J. Epidemiology of adult acute myeloid leukemia: Impact of exposures on clinical phenotypes and outcomes after therapy. Cancer Epidemiol. 2015 Dec;39(6):1084-92. doi: 10.1016/j.canep.2015.09.003. Epub 2015 Sep 11. PMID: 26365691.spa
dc.relation.references47 M. Heuser, Y. Ofran, N. Boissel, S. Brunet Mauri, C. Craddock, J. Janssen, A. Wierzbowska, C. Buske, on behalf of the ESMO Guidelines Committeespa
dc.relation.references48 M. Heuser, Y. Ofran, N. Boissel, S. Brunet Mauri, C. Craddock, J. Janssen, A. Wierzbowska, C. Buske, on behalf of the ESMO Guidelines Committeespa
dc.relation.references49 amamyan G, Kadia T, Ravandi F, Borthakur G, Cortes J, Jabbour E, Daver N, Ohanian M, Kantarjian H, Konopleva M. Frontline treatment of acute myeloid leukemia in adults. Crit Rev Oncol Hematol. 2017 Feb;110:20-34. doi: 10.1016/j.critrevonc.2016.12.004. Epub 2016 Dec 11. PMID: 28109402; PMCID: PMC5410376.spa
dc.relation.references50 Protocolo PETHEMA. Sociedad Española de Hematología y Hemoterapia, SEHH, https://www.sehh.es/servicios-para-los-socios/558-servicios-para-los socios/pethema/protocolos/lamspa
dc.relation.references51. Li D, Wang L, Zhu H, Dou L, Liu D, Fu L, Ma C, Ma X, Yao Y, Zhou L, Wang Q, Wang L, Zhao Y, Jing Y, Wang L, Li Y, Yu L. Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Intermediate-Risk Acute Myeloid Leukemia Adult Patients in First Complete Remission: A Meta-Analysis of Prospective Studies. PLoS One. 2015 Jul 21;10(7):e0132620. doi: 10.1371/journal.pone.0132620. PMID: 26197471; PMCID: PMC4510363spa
dc.contributor.cvlacSossa Melo, Claudia Lucía [0001425704]spa
dc.contributor.cvlacOchoa Vera, Miguel Enrique [0000898465]spa
dc.contributor.googlescholarSossa Melo, Claudia Lucía [es&oi=ao]spa
dc.contributor.orcidSossa Melo, Claudia Lucía [0000-0001-9876-222X]spa
dc.contributor.orcidOchoa Vera, Miguel Enrique [0000-0002-4552-3388]spa
dc.contributor.researchgateSossa Melo, Claudia Lucía [Claudia-Sossa]spa
dc.contributor.researchgateOchoa Vera, Miguel Enrique [Miguel-Ochoa-6]spa
dc.subject.lembMedicina internaspa
dc.subject.lembMedicinaspa
dc.subject.lembCiencias médicasspa
dc.subject.lembNeoplasiaspa
dc.subject.lembCondiciones precancerossasspa
dc.subject.lembLeucemia mieloide agudaspa
dc.subject.lembAnormalidades genéticasspa
dc.identifier.repourlrepourl:https://repository.unab.edu.cospa
dc.description.abstractenglishIntroduction: Acute myeloid leukemia (AML) is the most common acute leukemia in adults, with an overall 5-year survival of 27.7%, however compared to previous periods this has improved thanks to a better understanding of the different prognostic factors that include those related to the patient and the disease, but their impact on the clinical results of patients with AML at the FOSCAL clinic are not known. Objective: To identify prognostic association factors regarding overall survival and event-free survival in the cohort of patients with acute myeloid leukemia from the FOSCAL clinic, in the period from January 1, 2009 to June 30, 2021. Materials and methods: sociodemographic information and clinical characteristics of patients with AML treated at FOSCAL were retrospectively recorded. The characteristics of the patients at diagnosis are described; Kaplan Meier analysis was used to assess overall survival and event-free survival. The hazzard ratio and 95% confidence intervals crude and adjusted for covariates were also calculated.spa
dc.subject.proposalCiencias de la saludspa
dc.subject.proposalCáncerspa
dc.subject.proposalLeucemiasspa
dc.subject.proposalEnfermedad residual mediblespa
dc.type.redcolhttp://purl.org/redcol/resource_type/TM
dc.rights.creativecommonsAtribución-NoComercial-SinDerivadas 2.5 Colombia*
dc.coverage.campusUNAB Campus Bucaramangaspa
dc.description.learningmodalityModalidad Presencialspa


Ficheros en el ítem

Thumbnail
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial-SinDerivadas 2.5 Colombia
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución-NoComercial-SinDerivadas 2.5 Colombia